Do analysts rate HQH or HLNE?

Hamilton Lane has a consensus target price of $126.63, indicating a potential upside of 45.48%. Given Hamilton Lane's stronger consensus rating and higher probable upside, analysts clearly believe Hamilton Lane is more favorable than abrdn Healthcare Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score abrdn Healthcare Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Hamilton Lane 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90

Which has higher valuation & earnings, HQH or HLNE?

Hamilton Lane has higher revenue and earnings than abrdn Healthcare Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Healthcare Investors $253.93M 4.45 N/A N/A N/A Hamilton Lane $758.99M 6.37 $249.18M $6.56 13.27

Does the media prefer HQH or HLNE?

In the previous week, Hamilton Lane had 8 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 9 mentions for Hamilton Lane and 1 mentions for abrdn Healthcare Investors. Hamilton Lane's average media sentiment score of 0.58 beat abrdn Healthcare Investors' score of 0.00 indicating that Hamilton Lane is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment abrdn Healthcare Investors 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hamilton Lane 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer HQH or OTF?

Blue Owl Technology Finance has a consensus target price of $13.60, suggesting a potential upside of 42.01%. Given Blue Owl Technology Finance's stronger consensus rating and higher possible upside, analysts clearly believe Blue Owl Technology Finance is more favorable than abrdn Healthcare Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score abrdn Healthcare Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Blue Owl Technology Finance 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57

Which has preferable valuation and earnings, HQH or OTF?

Blue Owl Technology Finance has higher revenue and earnings than abrdn Healthcare Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Healthcare Investors $253.93M 4.45 N/A N/A N/A Blue Owl Technology Finance $1.15B 3.83 $720.37M $0.80 11.97

Do analysts recommend HQH or MC?

Moelis & Company has a consensus target price of $73.63, indicating a potential upside of 30.84%. Given Moelis & Company's stronger consensus rating and higher possible upside, analysts clearly believe Moelis & Company is more favorable than abrdn Healthcare Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score abrdn Healthcare Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Moelis & Company 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10

Which has higher valuation and earnings, HQH or MC?

Moelis & Company has higher revenue and earnings than abrdn Healthcare Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Healthcare Investors $253.93M 4.45 N/A N/A N/A Moelis & Company $1.52B 2.90 $233.04M $2.87 19.61

Does the media refer more to HQH or MC?

In the previous week, Moelis & Company had 3 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 4 mentions for Moelis & Company and 1 mentions for abrdn Healthcare Investors. abrdn Healthcare Investors' average media sentiment score of 0.00 beat Moelis & Company's score of -0.15 indicating that abrdn Healthcare Investors is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment abrdn Healthcare Investors 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moelis & Company 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend FHI or HQH?

Federated Hermes presently has a consensus target price of $57.40, indicating a potential upside of 2.37%. Given Federated Hermes' stronger consensus rating and higher possible upside, analysts plainly believe Federated Hermes is more favorable than abrdn Healthcare Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Federated Hermes 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.38 abrdn Healthcare Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, FHI or HQH?

Federated Hermes has higher revenue and earnings than abrdn Healthcare Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Federated Hermes $1.80B 2.32 $403.30M $5.38 10.42 abrdn Healthcare Investors $253.93M 4.45 N/A N/A N/A

Does the media favor FHI or HQH?

In the previous week, Federated Hermes had 4 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 5 mentions for Federated Hermes and 1 mentions for abrdn Healthcare Investors. Federated Hermes' average media sentiment score of 0.49 beat abrdn Healthcare Investors' score of 0.00 indicating that Federated Hermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Federated Hermes 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral abrdn Healthcare Investors 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer HQH or LAZ?

Lazard has a consensus target price of $49.88, indicating a potential upside of 38.33%. Given Lazard's stronger consensus rating and higher possible upside, analysts clearly believe Lazard is more favorable than abrdn Healthcare Investors. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score abrdn Healthcare Investors 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Lazard 2 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.18

Which has higher earnings and valuation, HQH or LAZ?

Lazard has higher revenue and earnings than abrdn Healthcare Investors. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio abrdn Healthcare Investors $253.93M 4.45 N/A N/A N/A Lazard $3.10B 1.29 $236.83M $2.04 17.67

Does the media refer more to HQH or LAZ?

In the previous week, Lazard had 8 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 9 mentions for Lazard and 1 mentions for abrdn Healthcare Investors. Lazard's average media sentiment score of 0.43 beat abrdn Healthcare Investors' score of 0.00 indicating that Lazard is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment abrdn Healthcare Investors 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lazard 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

abrdn Healthcare Investors (HQH) Competitors

$19.75 -0.63 (-3.08%)

Closing price 10/2/2026 03:58 PM Eastern

Extended Trading

$19.79 +0.04 (+0.19%)

As of 10/2/2026 07:30 PM Eastern

Compare

HQH vs. HLNE, OTF, MC, FHI, and LAZ

Should you buy abrdn Healthcare Investors stock or one of its competitors? abrdn Healthcare Investors's main competitors and comparable companies include Hamilton Lane (HLNE), Blue Owl Technology Finance (OTF), Moelis & Company (MC), Federated Hermes (FHI), and Lazard (LAZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "capital markets" industry.

How does abrdn Healthcare Investors compare to Hamilton Lane?

abrdn Healthcare Investors (NYSE:HQH) and Hamilton Lane (NASDAQ:HLNE) are both finance companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk, earnings and dividends.

abrdn Healthcare Investors has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Hamilton Lane has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Hamilton Lane has a net margin of 32.14% compared to abrdn Healthcare Investors' net margin of 0.00%. Hamilton Lane's return on equity of 25.10% beat abrdn Healthcare Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Healthcare Investors	N/A	N/A	N/A
Hamilton Lane	32.14%	25.10%	15.75%

In the previous week, Hamilton Lane had 8 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 9 mentions for Hamilton Lane and 1 mentions for abrdn Healthcare Investors. Hamilton Lane's average media sentiment score of 0.58 beat abrdn Healthcare Investors' score of 0.00 indicating that Hamilton Lane is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
abrdn Healthcare Investors	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hamilton Lane	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

32.6% of abrdn Healthcare Investors shares are owned by institutional investors. Comparatively, 97.4% of Hamilton Lane shares are owned by institutional investors. 7.3% of abrdn Healthcare Investors shares are owned by insiders. Comparatively, 24.0% of Hamilton Lane shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

abrdn Healthcare Investors pays an annual dividend of $2.47 per share and has a dividend yield of 12.5%. Hamilton Lane pays an annual dividend of $2.40 per share and has a dividend yield of 2.8%. Hamilton Lane pays out 36.6% of its earnings in the form of a dividend. Hamilton Lane has raised its dividend for 8 consecutive years.

Hamilton Lane has a consensus target price of $126.63, indicating a potential upside of 45.48%. Given Hamilton Lane's stronger consensus rating and higher probable upside, analysts clearly believe Hamilton Lane is more favorable than abrdn Healthcare Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
abrdn Healthcare Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Hamilton Lane	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90

Hamilton Lane has higher revenue and earnings than abrdn Healthcare Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Healthcare Investors	$253.93M	4.45	N/A	N/A	N/A
Hamilton Lane	$758.99M	6.37	$249.18M	$6.56	13.27

Summary

Hamilton Lane beats abrdn Healthcare Investors on 15 of the 17 factors compared between the two stocks.

How does abrdn Healthcare Investors compare to Blue Owl Technology Finance?

abrdn Healthcare Investors (NYSE:HQH) and Blue Owl Technology Finance (NYSE:OTF) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

abrdn Healthcare Investors pays an annual dividend of $2.47 per share and has a dividend yield of 12.5%. Blue Owl Technology Finance pays an annual dividend of $1.40 per share and has a dividend yield of 14.6%. Blue Owl Technology Finance pays out 175.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

32.6% of abrdn Healthcare Investors shares are owned by institutional investors. 7.3% of abrdn Healthcare Investors shares are owned by insiders. Comparatively, 0.1% of Blue Owl Technology Finance shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Blue Owl Technology Finance had 3 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 4 mentions for Blue Owl Technology Finance and 1 mentions for abrdn Healthcare Investors. Blue Owl Technology Finance's average media sentiment score of 0.33 beat abrdn Healthcare Investors' score of 0.00 indicating that Blue Owl Technology Finance is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
abrdn Healthcare Investors	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Blue Owl Technology Finance	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Blue Owl Technology Finance has higher revenue and earnings than abrdn Healthcare Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Healthcare Investors	$253.93M	4.45	N/A	N/A	N/A
Blue Owl Technology Finance	$1.15B	3.83	$720.37M	$0.80	11.97

Blue Owl Technology Finance has a consensus target price of $13.60, suggesting a potential upside of 42.01%. Given Blue Owl Technology Finance's stronger consensus rating and higher possible upside, analysts clearly believe Blue Owl Technology Finance is more favorable than abrdn Healthcare Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
abrdn Healthcare Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Blue Owl Technology Finance	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

abrdn Healthcare Investors has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Blue Owl Technology Finance has a beta of -0.58, suggesting that its share price is 158% less volatile than the broader market.

Blue Owl Technology Finance has a net margin of 28.69% compared to abrdn Healthcare Investors' net margin of 0.00%. Blue Owl Technology Finance's return on equity of 7.17% beat abrdn Healthcare Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Healthcare Investors	N/A	N/A	N/A
Blue Owl Technology Finance	28.69%	7.17%	3.86%

Summary

Blue Owl Technology Finance beats abrdn Healthcare Investors on 10 of the 15 factors compared between the two stocks.

How does abrdn Healthcare Investors compare to Moelis & Company?

abrdn Healthcare Investors (NYSE:HQH) and Moelis & Company (NYSE:MC) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Moelis & Company has a net margin of 14.50% compared to abrdn Healthcare Investors' net margin of 0.00%. Moelis & Company's return on equity of 39.59% beat abrdn Healthcare Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Healthcare Investors	N/A	N/A	N/A
Moelis & Company	14.50%	39.59%	17.04%

32.6% of abrdn Healthcare Investors shares are owned by institutional investors. Comparatively, 91.5% of Moelis & Company shares are owned by institutional investors. 7.3% of abrdn Healthcare Investors shares are owned by company insiders. Comparatively, 6.3% of Moelis & Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Moelis & Company had 3 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 4 mentions for Moelis & Company and 1 mentions for abrdn Healthcare Investors. abrdn Healthcare Investors' average media sentiment score of 0.00 beat Moelis & Company's score of -0.15 indicating that abrdn Healthcare Investors is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
abrdn Healthcare Investors	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moelis & Company	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

abrdn Healthcare Investors has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Moelis & Company has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

abrdn Healthcare Investors pays an annual dividend of $2.47 per share and has a dividend yield of 12.5%. Moelis & Company pays an annual dividend of $2.60 per share and has a dividend yield of 4.6%. Moelis & Company pays out 90.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Moelis & Company has raised its dividend for 1 consecutive years.

Moelis & Company has higher revenue and earnings than abrdn Healthcare Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Healthcare Investors	$253.93M	4.45	N/A	N/A	N/A
Moelis & Company	$1.52B	2.90	$233.04M	$2.87	19.61

Moelis & Company has a consensus target price of $73.63, indicating a potential upside of 30.84%. Given Moelis & Company's stronger consensus rating and higher possible upside, analysts clearly believe Moelis & Company is more favorable than abrdn Healthcare Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
abrdn Healthcare Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moelis & Company	1 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.10

Summary

Moelis & Company beats abrdn Healthcare Investors on 11 of the 16 factors compared between the two stocks.

How does abrdn Healthcare Investors compare to Federated Hermes?

Federated Hermes (NYSE:FHI) and abrdn Healthcare Investors (NYSE:HQH) are both finance companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Federated Hermes has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, abrdn Healthcare Investors has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

Federated Hermes has a net margin of 21.30% compared to abrdn Healthcare Investors' net margin of 0.00%. Federated Hermes' return on equity of 34.03% beat abrdn Healthcare Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Federated Hermes	21.30%	34.03%	18.54%
abrdn Healthcare Investors	N/A	N/A	N/A

In the previous week, Federated Hermes had 4 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 5 mentions for Federated Hermes and 1 mentions for abrdn Healthcare Investors. Federated Hermes' average media sentiment score of 0.49 beat abrdn Healthcare Investors' score of 0.00 indicating that Federated Hermes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Federated Hermes	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
abrdn Healthcare Investors	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.9% of Federated Hermes shares are owned by institutional investors. Comparatively, 32.6% of abrdn Healthcare Investors shares are owned by institutional investors. 4.2% of Federated Hermes shares are owned by insiders. Comparatively, 7.3% of abrdn Healthcare Investors shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Federated Hermes has higher revenue and earnings than abrdn Healthcare Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Federated Hermes	$1.80B	2.32	$403.30M	$5.38	10.42
abrdn Healthcare Investors	$253.93M	4.45	N/A	N/A	N/A

Federated Hermes presently has a consensus target price of $57.40, indicating a potential upside of 2.37%. Given Federated Hermes' stronger consensus rating and higher possible upside, analysts plainly believe Federated Hermes is more favorable than abrdn Healthcare Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Federated Hermes	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
abrdn Healthcare Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Federated Hermes pays an annual dividend of $1.52 per share and has a dividend yield of 2.7%. abrdn Healthcare Investors pays an annual dividend of $2.47 per share and has a dividend yield of 12.5%. Federated Hermes pays out 28.3% of its earnings in the form of a dividend. Federated Hermes has raised its dividend for 4 consecutive years.

Summary

Federated Hermes beats abrdn Healthcare Investors on 12 of the 17 factors compared between the two stocks.

How does abrdn Healthcare Investors compare to Lazard?

abrdn Healthcare Investors (NYSE:HQH) and Lazard (NYSE:LAZ) are both finance companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Lazard has higher revenue and earnings than abrdn Healthcare Investors.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
abrdn Healthcare Investors	$253.93M	4.45	N/A	N/A	N/A
Lazard	$3.10B	1.29	$236.83M	$2.04	17.67

abrdn Healthcare Investors pays an annual dividend of $2.47 per share and has a dividend yield of 12.5%. Lazard pays an annual dividend of $2.00 per share and has a dividend yield of 5.5%. Lazard pays out 98.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, Lazard had 8 more articles in the media than abrdn Healthcare Investors. MarketBeat recorded 9 mentions for Lazard and 1 mentions for abrdn Healthcare Investors. Lazard's average media sentiment score of 0.43 beat abrdn Healthcare Investors' score of 0.00 indicating that Lazard is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
abrdn Healthcare Investors	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lazard	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lazard has a net margin of 6.95% compared to abrdn Healthcare Investors' net margin of 0.00%. Lazard's return on equity of 23.58% beat abrdn Healthcare Investors' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
abrdn Healthcare Investors	N/A	N/A	N/A
Lazard	6.95%	23.58%	4.63%

Lazard has a consensus target price of $49.88, indicating a potential upside of 38.33%. Given Lazard's stronger consensus rating and higher possible upside, analysts clearly believe Lazard is more favorable than abrdn Healthcare Investors.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
abrdn Healthcare Investors	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Lazard	2 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.18

32.6% of abrdn Healthcare Investors shares are held by institutional investors. Comparatively, 54.8% of Lazard shares are held by institutional investors. 7.3% of abrdn Healthcare Investors shares are held by insiders. Comparatively, 1.0% of Lazard shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

abrdn Healthcare Investors has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Lazard has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Summary

Lazard beats abrdn Healthcare Investors on 11 of the 15 factors compared between the two stocks.

Get abrdn Healthcare Investors News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HQH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HQH vs. The Competition

Export

Metric	abrdn Healthcare Investors	Capital Markets Industry	Finance Sector	NYSE Exchange
Market Cap	$1.17B	$5.18B	$13.39B	$22.64B
Dividend Yield	11.82%	7.56%	6.03%	3.73%
P/E Ratio	N/A	29.43	24.50	27.75
Price / Sales	4.45	1,187.85	498.42	96.41
Price / Cash	N/A	47.77	46.45	38.88
Price / Book	N/A	3.49	2.70	4.64
Net Income	N/A	$417.69M	$1.32B	$1.08B
7 Day Performance	-7.22%	-0.71%	-1.04%	-1.06%
1 Month Performance	-12.71%	4.84%	0.36%	-5.49%
1 Year Performance	6.15%	11.38%	11.52%	5.13%

abrdn Healthcare Investors Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HQH abrdn Healthcare Investors	N/A	$19.75 -3.1%	N/A	+7.3%	$1.17B	$253.93M	N/A	147,000	News Coverage High Trading Volume
HLNE Hamilton Lane	4.7525 of 5 stars	$85.87 +1.1%	$131.57 +53.2%	-31.2%	$4.72B	$758.99M	13.09	785	News Coverage Analyst Forecast
OTF Blue Owl Technology Finance	4.76 of 5 stars	$10.23 +0.1%	$13.60 +33.0%	N/A	$4.68B	$1.15B	12.79	N/A	News Coverage
MC Moelis & Company	4.7994 of 5 stars	$58.01 -0.2%	$73.63 +26.9%	-18.3%	$4.55B	$1.52B	20.21	1,416	News Coverage Analyst Forecast
FHI Federated Hermes	2.5949 of 5 stars	$57.44 -0.2%	$57.40 -0.1%	+9.2%	$4.30B	$1.93B	10.68	2,091

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:HQH) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

abrdn Healthcare Investors (HQH) Competitors

HQH vs. HLNE, OTF, MC, FHI, and LAZ

How does abrdn Healthcare Investors compare to Hamilton Lane?

Summary

How does abrdn Healthcare Investors compare to Blue Owl Technology Finance?

Summary

How does abrdn Healthcare Investors compare to Moelis & Company?

Summary

How does abrdn Healthcare Investors compare to Federated Hermes?

Summary

How does abrdn Healthcare Investors compare to Lazard?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQH vs. The Competition

abrdn Healthcare Investors Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

abrdn Healthcare Investors (HQH) Competitors

HQH vs. HLNE, OTF, MC, FHI, and LAZ

How does abrdn Healthcare Investors compare to Hamilton Lane?

Which has more risk & volatility, HQH or HLNE?

Is HQH or HLNE more profitable?

Does the media prefer HQH or HLNE?

Do insiders & institutionals have more ownership in HQH or HLNE?

Is HQH or HLNE a better dividend stock?

Do analysts rate HQH or HLNE?

Which has higher valuation & earnings, HQH or HLNE?

Summary

How does abrdn Healthcare Investors compare to Blue Owl Technology Finance?

Is HQH or OTF a better dividend stock?

Do institutionals & insiders have more ownership in HQH or OTF?

Does the media prefer HQH or OTF?

Which has preferable valuation and earnings, HQH or OTF?

Do analysts prefer HQH or OTF?

Which has more risk & volatility, HQH or OTF?

Is HQH or OTF more profitable?

Summary

How does abrdn Healthcare Investors compare to Moelis & Company?

Is HQH or MC more profitable?

Do institutionals & insiders hold more shares of HQH or MC?

Does the media refer more to HQH or MC?

Which has more volatility & risk, HQH or MC?

Is HQH or MC a better dividend stock?

Which has higher valuation and earnings, HQH or MC?

Do analysts recommend HQH or MC?

Summary

How does abrdn Healthcare Investors compare to Federated Hermes?

Which has more risk & volatility, FHI or HQH?

Is FHI or HQH more profitable?

Does the media favor FHI or HQH?

Do institutionals & insiders believe in FHI or HQH?

Which has stronger valuation & earnings, FHI or HQH?

Do analysts recommend FHI or HQH?

Is FHI or HQH a better dividend stock?

Summary

How does abrdn Healthcare Investors compare to Lazard?

Which has higher earnings and valuation, HQH or LAZ?

Is HQH or LAZ a better dividend stock?

Does the media refer more to HQH or LAZ?

Is HQH or LAZ more profitable?

Do analysts prefer HQH or LAZ?

Do institutionals and insiders hold more shares of HQH or LAZ?

Which has more volatility and risk, HQH or LAZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HQH vs. The Competition

abrdn Healthcare Investors Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools